Loading...
The efficacy of PSA screening: impact of key components in the ERSPC and PLCO trial
BACKGROUND: The European Randomized Study of Screening for Prostate Cancer (ERSPC) showed that prostate-specific antigen (PSA) screening significantly reduced prostate cancer mortality (rate ratio (RR)=0.79, 95%CI 0.69–0.91). The U.S. Prostate, Lung, Colorectal, and Ovarian (PLCO) trial showed no su...
Saved in:
| Published in: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5839977/ https://ncbi.nlm.nih.gov/pubmed/29211316 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31178 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|